Who is sponsoring NCT03348059?

NCT03348059 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT03348059?

Interventions in NCT03348059: Direct-acting antiviral therapy.

What condition does NCT03348059 study?

NCT03348059 studies Chronic Hepatitis c.

Is NCT03348059 still recruiting?

NCT03348059 is currently completed. Last updated 20 November 2017.

Last reviewed 2017-11-20 · How we verify

NCT03348059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

Completed Last updated 20 November 2017

What this trial tests

trial testing Direct-acting antiviral therapy in Chronic Hepatitis c in 103 participants. Completed in 31 March 2017.

Timeline

1 October 2015

Primary endpoint
30 November 2016

31 March 2017

Quick facts

Lead sponsor	Hospices Civils de Lyon
Status	Completed
Study type	OBSERVATIONAL
Enrollment	103
Start date	1 October 2015
Primary completion	30 November 2016
Estimated completion	31 March 2017
Sites	1 location across France

Drugs / interventions tested

Direct-acting antiviral therapy — full drug profile →

Conditions studied

Chronic Hepatitis c — all drugs for Chronic Hepatitis c →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Chronic Hepatitis c. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03348059 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 20 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03348059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing